Amended Claims

1. A PTH conjugate, in which a PTH moiety is reversibly conjugated to a polymeric moiety or fatty acid-based moiety, or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said PTH conjugate or pharmaceutically acceptable salt thereof for use in the treatment of hypoparathyroidism, wherein the starting dose ranges from 0.8 to 4.9 nmol/day and wherein the PTH conjugate is of formula (IIf-i):



(IIf-i),

wherein

the unmarked dashed line indicates the attachment to the N-terminal amine functional group of a PTH moiety having the sequence of SEQ ID NO:51 by forming an amide bond; and

the dashed line marked with the asterisk indicates attachment to a moiety



wherein

m and p are independently an integer ranging from and including 400 to 500..

2. The PTH conjugate of claim 1, wherein the starting dose ranges from 2.9 to 4.5 nmol/day.

3. The PTH conjugate of claim 1, wherein the starting dose ranges from 3.6 to 4.4 nmol/day.

4. The PTH conjugate of claim 1, wherein the starting dose ranges from 0.8 to 3.9 nmol/day.

5. The PTH conjugate of claim 1 or 4, wherein the starting dose ranges from 1.5 to 3.4 nmol/day.

6. The PTH conjugate of any one of claims 1, 4 or 5, wherein the starting dose is 2.9 ± 0.3 nmol/day.

7. The PTH conjugate of claim 1, wherein the starting dose is 4.3 ± 0.3 nmol/day.

8. The PTH conjugate of claim 1 or 7, wherein the starting dose is 4.3 ± 0.2 nmol/day.

9. The PTH conjugate of claim 1 or 7, wherein the starting dose is 4.3 ± 0.1 nmol/day.

10. The PTH conjugate of any one of claims 1 to 9, wherein the starting dose is to be administered to a patient as one subcutaneous injection.

11. Use of the PTH conjugate or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said PTH conjugate or pharmaceutically acceptable salt thereof of any one of claims 1 to 10 in the manufacture of a medicament for the treatment of hypoparathyroidism.

12. Use of a PTH conjugate of any one of claims 1 to 10, in which a PTH moiety is reversibly conjugated to a polymeric moiety or fatty acid-based moiety, or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said PTH conjugate or pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of hypoparathyroidism, wherein the medicament is to be administered at a starting dose that ranges from 0.8 to 4.9 nmol/day.